FDA Approves Jideytro (Zidesamtinib) for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer

A New Targeted Treatment Option for Patients with ROS1-Positive Lung Cancer

The US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a new targeted therapy developed for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have previously received treatment with a ROS1 kinase inhibitor.

The approval marks an important development for people living with this rare form of lung cancer, particularly patients whose disease has progressed after earlier targeted therapies. Jideytro is designed to address some of the ongoing challenges in ROS1-positive NSCLC treatment, including resistance mutations, disease spread to the brain, and the need for treatments that can offer sustained disease control with manageable side effects.

The approval was announced by GSK plc on July 22, 2026, following the completion of its acquisition of Nuvalent, Inc., which developed zidesamtinib.

Understanding ROS1-Positive Non-Small Cell Lung Cancer

Non-small cell lung cancer is the most common type of lung cancer. While many cases are associated with smoking, ROS1-positive NSCLC often occurs in younger adults and people who have never smoked.

ROS1-positive lung cancer is caused by changes in the ROS1 gene, which can lead to uncontrolled cancer cell growth. Although ROS1-positive NSCLC represents a small percentage of all lung cancer cases, thousands of patients worldwide are diagnosed with this condition each year.

One of the major challenges in treating ROS1-positive NSCLC is that cancer cells can develop resistance to existing therapies over time. In addition, the disease can spread to the central nervous system, including the brain, creating additional treatment challenges.

How Jideytro Works

Jideytro is a selective ROS1 inhibitor designed to block ROS1 signaling, which plays a role in the growth and survival of cancer cells.

The medicine was developed with several goals:

• Targeting ROS1-driven cancer activity with high selectivity
• Providing broader coverage against ROS1 resistance mutations
• Reaching cancer cells that have spread to the brain through blood-brain barrier penetration
• Supporting longer-lasting treatment responses

These features are intended to help patients maintain control of their disease while addressing some limitations seen with earlier ROS1-targeted treatments.

FDA Approval Based on ARROS-1 Clinical Trial Results

The FDA approval was supported by results from the global ARROS-1 Phase I/II clinical trial, which evaluated zidesamtinib in patients with advanced ROS1-positive NSCLC who had previously received a ROS1 inhibitor.

The study included 117 patients with previously treated ROS1-positive NSCLC. Results showed meaningful and durable responses:

• The objective response rate was 44%
• The duration of response at six months was 82%
• The duration of response at 12 months was 69%

Responses were also observed in patients with brain metastases and those whose cancers carried ROS1 resistance mutations.

Researchers involved in the study highlighted that these findings represent progress for patients who have limited treatment options after disease progression following earlier ROS1-directed therapies.

Safety Profile and Common Side Effects

Like all medicines, Jideytro may cause side effects. In the pooled safety population of 446 patients, the most common adverse reactions reported in at least 15% of patients included:

• Oedema or swelling
• Peripheral neuropathy, which may involve nerve-related symptoms such as tingling or numbness
• Constipation
• Fatigue
• Dyspnoea or shortness of breath

Healthcare professionals will continue to monitor patients receiving Jideytro to manage potential side effects and help maintain treatment quality.

A New Milestone in Lung Cancer Treatment Development

The approval of Jideytro represents GSK’s first approved medicine in lung cancer and expands the company’s oncology portfolio into targeted treatments for solid tumours.

Tony Wood, Chief Scientific Officer at GSK, said the approval reflects the importance of developing medicines for patients with significant unmet medical needs. The company stated that Jideytro supports its strategy of investing in therapies aimed at validated cancer targets.

The company is also advancing additional oncology programmes, including treatments targeting ALK-altered NSCLC, HER2-altered NSCLC, and other tumour types.

What This Approval Means for Patients

For patients with ROS1-positive NSCLC, treatment decisions often involve balancing cancer control with quality of life. While existing therapies have improved outcomes, resistance and disease progression remain significant concerns.

Jideytro provides another treatment option for adults whose cancer has progressed after previous ROS1 kinase inhibitor therapy. Its development reflects ongoing efforts to create more precise cancer treatments that address the changing biology of tumours.

Patient advocacy groups have also emphasized that people living with ROS1-positive lung cancer need therapies that not only extend survival but also support daily quality of life.

Future Research Into Zidesamtinib

Although Jideytro has received FDA approval for previously treated ROS1-positive NSCLC, research continues. Zidesamtinib is still being studied in the ARROS-1 clinical trial, including evaluation in patients who have not previously received ROS1 inhibitor treatment.

Future studies will help researchers better understand the potential role of this therapy across different stages of ROS1-positive cancers.

About ROS1-Positive NSCLC and Targeted Therapies

Advances in precision medicine have transformed lung cancer treatment by allowing doctors to identify specific genetic changes that can be targeted with specialised medicines.

Targeted therapies such as ROS1 inhibitors are designed to work differently from traditional chemotherapy by focusing on specific molecular drivers of cancer growth. This approach may provide more personalised treatment options for eligible patients.

However, treatment decisions should always be made with a qualified healthcare professional who can consider an individual patient’s medical history, cancer characteristics, and treatment goals.

Source: GSK plc announcement regarding FDA approval of Jideytro (zidesamtinib).

Disclaimer: This article is intended for informational purposes only and does not provide medical advice, diagnosis, or treatment recommendations. Patients should consult their healthcare provider for personalised medical guidance and information about available treatment options. Drug approvals, safety information, and treatment recommendations may change as additional research and regulatory updates become available.